Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 15,500 shares, a decline of 7.2% from the July 15th total of 16,700 shares. Based on an average daily trading volume, of 7,400 shares, the short-interest ratio is currently 2.1 days. Currently, 0.2% of the company’s shares are sold short.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals in a report on Wednesday, August 14th. They issued a “hold” rating for the company.
Check Out Our Latest Report on CPIX
Cumberland Pharmaceuticals Price Performance
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
- Five stocks we like better than Cumberland Pharmaceuticals
- How to Invest in the FAANG Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Airline Stocks – Top Airline Stocks to Buy Now
- 2 Option Strategies to Maximize Profits in a Bear Market
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.